Concord Drugs — 360° view

Concord Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹42 crore and net profit of ₹2.21 crore for the September 2026 quarter.

Concord Drugs (BSE: CONCORD) closed at ₹68.87 on 20 Nov 2026, down 15.3% over the past year. Its market capitalisation is ₹91 crore and it trades at 30.7 times earnings.

Share price
₹68.87 (20 Nov 2026)
Market cap
₹91 Cr (20 Nov 2026)
P/E
30.66 (20 Nov 2026)
Revenue
₹42 Cr (September 2026 quarter)
Net profit
₹2 Cr (September 2026 quarter)
ROCE
5.19% (FY26)
ROE
2.52% (FY26)
Book value
₹38.5 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹91.79 / ₹59.99 (20 Nov 2026)
1-year return
-15.3% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: CONCORD

Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on approved formulations

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.